Research Paper Volume 10, Issue 8 pp 1977—1988
Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling
- 1 Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
- 2 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 3 China National Clinical Research Center for Neurological Diseases, Beijing, China
- 4 Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China
received: June 20, 2018 ; accepted: August 6, 2018 ; published: August 15, 2018 ;https://doi.org/10.18632/aging.101521
How to Cite
Copyright: Wang et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Isocitrate dehydrogenase (IDH) mutations are the most common genetic aberrations in gliomagenesis. We aimed to build a high-efficiency prediction gene signature in patients with IDH-mutant glioma.
Methods: In total, 167 gliomas from Chinese Glioma Genome Atlas (CGGA) dataset were included for discovery. The Cancer Genome Atlas (TCGA) dataset was used for validation. R language was the main software environment for our statistical operation and graphics.
Results: We applied the Time-Dependent ROC Curve (timeROC) method to estimate the gene prediction accuracy of 3 years and 5 years in two datasets. Seven genes were selected for further analysis (AUC ≥ 0.7 in two datasets). A seven-gene enrichment score was established to predict the overall survival of 3 years and 5 years for IDH- mutant glioma patients. Moreover, the seven-gene signature was an independent prognostic indicator for patients with IDH-mutant glioma. Gene Ontology (GO) Analysis of associated genes revealed signature-related biological process of cell cycle and division.
Conclusion: We have identified a seven-gene signature that can provide a more accurate predictor of 3 years and 5 years for patients with IDH-mutant glioma. Moreover, the signature may potentially help neurosurgeons with the clinical personalized management of gliomas.